Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Agency: National Institutes of Health
Assistance Listings: 93.394 -- Cancer Detection and Diagnosis Research
Last Updated: June 3, 2026
Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have...
potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Eligibility
Eligible applicants
Nonprofit
- Other Native American tribal organizations
- Nonprofits non-higher education without 501(c)(3)
- Nonprofits non-higher education with 501(c)(3)
Government
- Federally recognized Native American tribal governments
- State governments
- Special district governments
- County governments
- Public and Indian housing authorities
- City or township governments
Business
- For-profit organizations other than small businesses
- Small businesses
Education
- Public and state institutions of higher education
- Private institutions of higher education
- Independent school districts
Miscellaneous
- Other
Additional information
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grantor contact information
Description
National Cancer Institute (NCI)
Kelly.crotty@nih.gov
Kelly.crotty@nih.gov
Documents
| File name | Description | Last updated |
|---|---|---|
| RFA-CA-27-001-Full-Announcement.html | RFA-CA-27-001-Full-Announcement.html | Jun 3, 2026 07:25 PM UTC |
Link to additional information
--
Closing: November 10, 2026
Award
$5,100,000
Program Funding
20
Expected awards
$--
Award Minimum
$150,000
Award Maximum
Funding opportunity number:
RFA-CA-27-001
Cost sharing or matching requirement:
No
Funding instrument type:
Grant
Opportunity Category:
Discretionary
Opportunity Category Explanation:
--
Category of Funding Activity:
Health
Category Explanation:
--
History
Version:
1
Posted date:
June 3, 2026
Archive date:
January 9, 2027
